BioPharma Dive September 4, 2024
At an anticipated investor day, the biotech revealed a new company organization and set targets for revenue, drug launches into early next decade.
BioMarin Pharmaceutical has brought eight rare disease drugs to market over the past 25 years, a record few companies in the biotechnology industry can match. But recently the company’s momentum has stalled and, over the past nine months, it has shed jobs, cut spending and shelved research projects in a major bid to revive its fortunes.
On Wednesday, executives unveiled their long-term plans for growth at an anticipated investor day, outlining guidance for revenue and new drug approvals over the next decade. They also debuted a new company structure that splits its business into three separate segments.
...Today's Sponsors
Today's Sponsor